JP2008533191A5 - - Google Patents

Download PDF

Info

Publication number
JP2008533191A5
JP2008533191A5 JP2008502453A JP2008502453A JP2008533191A5 JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5 JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008502453 A JP2008502453 A JP 2008502453A JP 2008533191 A5 JP2008533191 A5 JP 2008533191A5
Authority
JP
Japan
Prior art keywords
compound
compound according
alkyl
alaninyl
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008502453A
Other languages
English (en)
Japanese (ja)
Other versions
JP5345381B2 (ja
JP2008533191A (ja
Filing date
Publication date
Priority claimed from GBGB0505781.5A external-priority patent/GB0505781D0/en
Application filed filed Critical
Publication of JP2008533191A publication Critical patent/JP2008533191A/ja
Publication of JP2008533191A5 publication Critical patent/JP2008533191A5/ja
Application granted granted Critical
Publication of JP5345381B2 publication Critical patent/JP5345381B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008502453A 2005-03-21 2006-03-16 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体 Expired - Fee Related JP5345381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505781.5 2005-03-21
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013097919A Division JP5863702B2 (ja) 2005-03-21 2013-05-07 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体

Publications (3)

Publication Number Publication Date
JP2008533191A JP2008533191A (ja) 2008-08-21
JP2008533191A5 true JP2008533191A5 (US07794700-20100914-C00152.png) 2009-04-30
JP5345381B2 JP5345381B2 (ja) 2013-11-20

Family

ID=34531603

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008502453A Expired - Fee Related JP5345381B2 (ja) 2005-03-21 2006-03-16 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体
JP2013097919A Active JP5863702B2 (ja) 2005-03-21 2013-05-07 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013097919A Active JP5863702B2 (ja) 2005-03-21 2013-05-07 癌の治療における使用のためのヌクレオシド化合物のホスホルアミデート誘導体

Country Status (20)

Country Link
US (1) US8263575B2 (US07794700-20100914-C00152.png)
EP (1) EP1866324B1 (US07794700-20100914-C00152.png)
JP (2) JP5345381B2 (US07794700-20100914-C00152.png)
CN (2) CN101175763A (US07794700-20100914-C00152.png)
AT (1) ATE471334T1 (US07794700-20100914-C00152.png)
AU (1) AU2006226182C1 (US07794700-20100914-C00152.png)
BR (1) BRPI0609704B8 (US07794700-20100914-C00152.png)
CA (1) CA2602324C (US07794700-20100914-C00152.png)
CY (1) CY1111538T1 (US07794700-20100914-C00152.png)
DE (1) DE602006014949D1 (US07794700-20100914-C00152.png)
DK (1) DK1866324T3 (US07794700-20100914-C00152.png)
ES (1) ES2348741T3 (US07794700-20100914-C00152.png)
GB (1) GB0505781D0 (US07794700-20100914-C00152.png)
IL (1) IL186104A (US07794700-20100914-C00152.png)
MX (1) MX2007011666A (US07794700-20100914-C00152.png)
PL (1) PL1866324T3 (US07794700-20100914-C00152.png)
PT (1) PT1866324E (US07794700-20100914-C00152.png)
SI (1) SI1866324T1 (US07794700-20100914-C00152.png)
WO (1) WO2006100439A1 (US07794700-20100914-C00152.png)
ZA (1) ZA200709011B (US07794700-20100914-C00152.png)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
PE20120013A1 (es) 2009-01-09 2012-02-02 Univ Cardiff Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012092484A2 (en) * 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
CN104974206B (zh) * 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
MX2015006195A (es) * 2012-11-16 2015-12-08 Univ Cardiff Procedimiento para preparar profarmacos de nucleosidos.
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
US20170101431A1 (en) * 2014-05-28 2017-04-13 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
AU2015352203B2 (en) 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
AU2016355429B2 (en) 2015-11-16 2021-05-06 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
US11202792B2 (en) 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
CA2675757C (en) 1995-04-21 2011-03-15 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 3′−カルバモイルアルキルヌクレオシド誘導体
DE69900841T2 (de) * 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
EP1478322A4 (en) * 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物

Similar Documents

Publication Publication Date Title
JP2008533191A5 (US07794700-20100914-C00152.png)
JP2008505157A5 (US07794700-20100914-C00152.png)
JP2013537203A5 (US07794700-20100914-C00152.png)
JP2019512478A5 (US07794700-20100914-C00152.png)
JP2005523922A5 (US07794700-20100914-C00152.png)
JP2010530881A5 (US07794700-20100914-C00152.png)
JP2008528447A5 (US07794700-20100914-C00152.png)
JP2007511504A5 (US07794700-20100914-C00152.png)
JP2008510828A5 (US07794700-20100914-C00152.png)
JP2009535307A5 (US07794700-20100914-C00152.png)
JP2009520695A5 (US07794700-20100914-C00152.png)
JP2009502743A5 (US07794700-20100914-C00152.png)
JP2009504763A5 (US07794700-20100914-C00152.png)
JP2008510770A5 (US07794700-20100914-C00152.png)
JP2011509309A5 (US07794700-20100914-C00152.png)
JP2014503574A5 (US07794700-20100914-C00152.png)
JP2006514012A5 (US07794700-20100914-C00152.png)
JP2002516817A5 (US07794700-20100914-C00152.png)
JP2009500423A5 (US07794700-20100914-C00152.png)
JP2007501809A5 (US07794700-20100914-C00152.png)
JP2008508287A5 (US07794700-20100914-C00152.png)
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
MY145838A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
JP2003306481A5 (US07794700-20100914-C00152.png)
JP2018530582A5 (US07794700-20100914-C00152.png)